Medivie Therapeutic Ltd (MDVI) - Net Assets
Based on the latest financial reports, Medivie Therapeutic Ltd (MDVI) has net assets worth ILA-4.46 Million ILA (≈ $-11.95K USD) as of June 2021. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (ILA4.67 Million ≈ $12.53K USD) and total liabilities (ILA9.13 Million ≈ $24.49K USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Medivie Therapeutic Ltd asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ILA-4.46 Million |
| % of Total Assets | -95.36% |
| Annual Growth Rate | N/A |
| 5-Year Change | 546.27% |
| 10-Year Change | 2.05% |
| Growth Volatility | 984.21 |
Medivie Therapeutic Ltd - Net Assets Trend (2010–2020)
This chart illustrates how Medivie Therapeutic Ltd's net assets have evolved over time, based on quarterly financial data. Also explore Medivie Therapeutic Ltd balance sheet assets for the complete picture of this company's asset base.
Annual Net Assets for Medivie Therapeutic Ltd (2010–2020)
The table below shows the annual net assets of Medivie Therapeutic Ltd from 2010 to 2020. For live valuation and market cap data, see MDVI market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2020-12-31 | ILA3.73 Million ≈ $10.00K |
-36.58% |
| 2019-12-31 | ILA5.88 Million ≈ $15.76K |
-51.72% |
| 2018-12-31 | ILA12.18 Million ≈ $32.65K |
-25.11% |
| 2017-12-31 | ILA16.26 Million ≈ $43.60K |
+2718.72% |
| 2016-12-31 | ILA577.00K ≈ $1.55K |
+209.49% |
| 2015-12-31 | ILA-527.00K ≈ $-1.41K |
-123.36% |
| 2014-12-31 | ILA2.26 Million ≈ $6.05K |
+248.13% |
| 2013-12-31 | ILA-1.52 Million ≈ $-4.08K |
-224.73% |
| 2012-12-31 | ILA1.22 Million ≈ $3.27K |
-66.58% |
| 2011-12-31 | ILA3.65 Million ≈ $9.80K |
+164.29% |
| 2010-12-31 | ILA-5.68 Million ≈ $-15.24K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Medivie Therapeutic Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 5883300000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2020)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | ILA42.12 Million | 1109.78% |
| Other Components | ILA6.62 Million | 174.33% |
| Total Equity | ILA3.79 Million | 100.00% |
Medivie Therapeutic Ltd Competitors by Market Cap
The table below lists competitors of Medivie Therapeutic Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Upsellon Brands Holdings Ltd
TA:CHR
|
$517.79K |
|
Cobra Resources PLC
LSE:COBR
|
$518.11K |
|
SDCL EDGE Acquisition Corporation
NYSE:SEDA
|
$518.19K |
|
Enlivex Therapeutics Ltd
TA:ENLV
|
$519.31K |
|
SDM SE
XETRA:75S
|
$515.57K |
|
CORELENS S.A. ZY -10
F:9GK
|
$514.90K |
|
SolarWorld Aktiengesellschaft
HM:SWVK
|
$513.74K |
|
Hepion Pharmaceuticals Inc
NASDAQ:HEPA
|
$513.62K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Medivie Therapeutic Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2019 to 2020, total equity changed from 5,062,000 to 3,795,000, a change of -1,267,000 (-25.0%).
- Net loss of 6,594,000 reduced equity.
- Other factors increased equity by 5,327,000.
Equity Change Factors (2019 to 2020)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ILA-6.59 Million | -173.75% |
| Other Changes | ILA5.33 Million | +140.37% |
| Total Change | ILA- | -25.03% |
Book Value vs Market Value Analysis
This analysis compares Medivie Therapeutic Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 50.79x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 24.75x to 50.79x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | ILA2.71 | ILA67.00 | x |
| 2018-12-31 | ILA5.70 | ILA67.00 | x |
| 2019-12-31 | ILA2.31 | ILA67.00 | x |
| 2020-12-31 | ILA1.32 | ILA67.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Medivie Therapeutic Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -173.75%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1342.97%
- • Asset Turnover: 0.04x
- • Equity Multiplier: 3.21x
- Recent ROE (-173.75%) is above the historical average (-226.23%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2010 | 0.00% | -2151.56% | 0.21x | 0.00x | ILA-16.11 Million |
| 2011 | -245.74% | -1132.11% | 0.06x | 3.72x | ILA-9.02 Million |
| 2012 | -453.32% | -364.14% | 0.57x | 2.19x | ILA-5.66 Million |
| 2013 | 0.00% | -225.11% | 3.32x | 0.00x | ILA-3.78 Million |
| 2014 | -373.76% | -4216.00% | 0.05x | 1.76x | ILA-8.66 Million |
| 2015 | 0.00% | -2725.16% | 0.28x | 0.00x | ILA-4.28 Million |
| 2016 | -913.29% | -1837.21% | 0.11x | 4.59x | ILA-4.79 Million |
| 2017 | -86.16% | -2270.41% | 0.01x | 3.82x | ILA-4.97 Million |
| 2018 | -13.83% | 0.00% | 0.00x | 1.33x | ILA-2.95 Million |
| 2019 | -228.72% | -2382.30% | 0.04x | 2.67x | ILA-12.08 Million |
| 2020 | -173.75% | -1342.97% | 0.04x | 3.21x | ILA-6.97 Million |
Industry Comparison
This section compares Medivie Therapeutic Ltd's net assets metrics with peer companies in the Machinery, Tools, Heavy Vehicles, Trains & Ships industry.
No peer company data available for comparison.
About Medivie Therapeutic Ltd
Medivie Therapeutic Limited develops and markets dental devices. It offers Laboraide, a dental device that is placed between the woman's lower and upper jaw during birth, which allows the relaxation of the jaw, neck, and head muscles through the flow of oxygen to the muscles. The company also develops modular pacifiers that enables development of mouth structure and prevent future damage to the c… Read more